Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus delbrueckii + lactobacillus fermentum (Ain Shams University)
- Development stage
- Unknown
- Lead developer
- Ain Shams University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus delbrueckii and Lactobacillus fermentum are probiotic bacterial species that have been investigated for the treatment of Irritable Bowel Syndrome (IBS). In a clinical trial conducted by Ain Shams University, these probiotics were evaluated for their ability to improve symptoms in IBS patients, either as a standalone therapy compared to the prokinetic itopride hydrochloride or as an adjunctive treatment. The mechanism of action involves the modulation of the gut microbiota to correct dysbiosis, enhancement of the intestinal mucosal barrier, and potential reduction of low-grade inflammation and visceral hypersensitivity. These effects aim to alleviate common IBS symptoms such as abdominal pain, bloating, and altered bowel habits.
- Other names
- lactobacillus delbrueckiilactobacillus fermentumlactobacillus delbruekiiL. delbrueckiiL. fermentum
Beyond the preview
Go deeper on lactobacillus delbrueckii + lactobacillus fermentum (Ain Shams University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus delbrueckii + lactobacillus fermentum (Ain Shams University).